Pilot Study of the Combination of Melphalan, Carboplatin and Etoposide as a Conditioning Regimen for Relapsed Lymphoma Patients

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Acta Haematologica

• Publication date

  1999-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000040969PMID 10473890
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.

  1997cited by this paper
• High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin’s lymphoma: results of outpatient treatment in community cancer centers

  1997cited by this paper
• High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study*

  1996cited by this paper
• Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

  1995cited by this paper
• High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.

  1995cited by this paper
• Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.

  1995cited by this paper
• Acute cutaneous eruptions after marrow ablation: Roses by other names?

  1994cited by this paper
• Autologous graft-vs-host disease: mechanisms and potential therapeutic effect.

  1993cited by this paper
• High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer

  1991cited by this paper
• Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings.

  1990cited by this paper
• The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay.

  1988cited by this paper
• Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

  1988cited by this paper

• Cisplatin as a Viable and Secure Alternative to Carmustine in BEAM-Based Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma.

  2024cites this paper
• Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation

  2024cites this paper
• Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.

  2019cites this paper
• Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma

  2007cites this paper
• Current Status and Future of Relapsed Primary Central Nervous System Lymphoma (PCNSL)

  2003cites this paper